Skip to main content
[Preprint]. 2024 Apr 1:2024.03.27.586411. [Version 2] doi: 10.1101/2024.03.27.586411

Figure 1: Discovery and characterization of broadly neutralizing PDCoV monoclonal antibodies (mAbs).

Figure 1:

A, Immunization study of ATX mice with PDCoV S and RBD. B, Screening of isolated mAbs for neutralization of VSV pseudotyped with PDCoV S using HEK293T cells transfected with the galline APN (gAPN) receptor. Four neutralizing antibodies PD17, PD20, PD33 and PD41 were selected for further characterization. C, Biolayer interferometry (BLI) analysis of PDCoV RBDUSA_IL121_2014 binding to neutralizing antibodies PD17, PD20, PD33, and PD41 Fab fragments. D, Binding affinities of the PD33 and the PD41 Fab to PDCoV RBDUSA_IL121_2014 (dose-response curves are shown in Figure S2). E-F, PD33 (E) and PD41 (F) mAb-mediated neutralization of VSV pseudotyped with PDCoV S variants using HEK293T target cells transfected with human APN (hAPN). The bars correspond to geometric mean titers and each data point is one out of 3 biological replicates, each one using a different batch of pseudovirus.